Eli Frydman
Director/Miembro de la Junta en LifeBond Ltd. .
Perfil
Eli Frydman is currently a Director at LifeBond Ltd.
He previously held Director positions at Beta-O2 Technologies Ltd., PolyPid Ltd., and Nucleix Ltd.
He also served as COO & Vice President-Business Development at Aposense Ltd.
in 2011.
Frydman holds an MBA and a doctorate from Ecole Nationale des Ponts et Chaussées.
He also has an undergraduate degree from Tel-Aviv University and graduate and doctorate degrees from Weizmann Institute of Science.
Cargos activos de Eli Frydman
Empresas | Cargo | Inicio |
---|---|---|
LifeBond Ltd.
LifeBond Ltd. Medical SpecialtiesHealth Technology LifeBond Ltd. engages in the development of medical devices designed to restore and repair tissues to reduce post-operative complications. The company was founded by Nir Mashkif, Orahn Preiss-Bloom and Ishay Attar in 2007 and is headquartered in Caesarea, Israel. | Director/Miembro de la Junta | - |
Antiguos cargos conocidos de Eli Frydman.
Empresas | Cargo | Fin |
---|---|---|
POLYPID LTD. | Director/Miembro de la Junta | - |
Beta-O2 Technologies Ltd.
Beta-O2 Technologies Ltd. Medical SpecialtiesHealth Technology Beta-O2 Technologies Ltd. develops implantable bio-artificial pancreas devices. It offers BAir, a bio-artificial pancreas that provides a viable environment for islets of Langerhans to thrive and provide the body with insulin on demand. The company was founded by Pnina Vardi, Konstantin Bloch, and Yossi Gross in 2004 and is headquartered in Rosh-Haayin, Israel. | Director/Miembro de la Junta | - |
Nucleix Ltd.
Nucleix Ltd. Medical/Nursing ServicesHealth Services Nucleix Ltd. develops, manufactures and markets non-invasive molecular cancer diagnostic tests. Its product Bladder EpiCheck is a urine test for monitoring of bladder cancer. The firm provides diagnostic tests for lung and colorectal cancer detection from blood samples, using its proprietary and highly innovative technology. The company was founded by Adam Wasserstrom, Dan Frumkin, and Elon A. Ganor in 2008 and is headquartered in Rehovot, Israel. | Director/Miembro de la Junta | - |
APOSENSE LTD | Director de Operaciones | - |
Formación de Eli Frydman.
Ecole Nationale des Ponts et Chaussées | Doctorate Degree |
Tel-Aviv University | Undergraduate Degree |
Weizmann Institute of Science | Graduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
Empresas cotizadas | 1 |
---|---|
POLYPID LTD. | Health Technology |
Empresas privadas | 4 |
---|---|
Aposense Ltd.
Aposense Ltd. Pharmaceuticals: MajorHealth Technology Aposense Ltd. engages in the provision of proprietary conjugates. It offers platform technology which comprises the rational design of small molecular moieties with the increased affinity to the cell membranes imparting the conjugates compound with improved drug properties such as extended life span oral bioavailabity and selective at target site. The company was founded by Ilan Ziv and Jacob Gottenstein on October 9, 1996 and is headquartered in Petach-Tikva, Israel. | Health Technology |
LifeBond Ltd.
LifeBond Ltd. Medical SpecialtiesHealth Technology LifeBond Ltd. engages in the development of medical devices designed to restore and repair tissues to reduce post-operative complications. The company was founded by Nir Mashkif, Orahn Preiss-Bloom and Ishay Attar in 2007 and is headquartered in Caesarea, Israel. | Health Technology |
Beta-O2 Technologies Ltd.
Beta-O2 Technologies Ltd. Medical SpecialtiesHealth Technology Beta-O2 Technologies Ltd. develops implantable bio-artificial pancreas devices. It offers BAir, a bio-artificial pancreas that provides a viable environment for islets of Langerhans to thrive and provide the body with insulin on demand. The company was founded by Pnina Vardi, Konstantin Bloch, and Yossi Gross in 2004 and is headquartered in Rosh-Haayin, Israel. | Health Technology |
Nucleix Ltd.
Nucleix Ltd. Medical/Nursing ServicesHealth Services Nucleix Ltd. develops, manufactures and markets non-invasive molecular cancer diagnostic tests. Its product Bladder EpiCheck is a urine test for monitoring of bladder cancer. The firm provides diagnostic tests for lung and colorectal cancer detection from blood samples, using its proprietary and highly innovative technology. The company was founded by Adam Wasserstrom, Dan Frumkin, and Elon A. Ganor in 2008 and is headquartered in Rehovot, Israel. | Health Services |
- Bolsa de valores
- Insiders
- Eli Frydman